This analysis revealed that persisting inflammatory parameters, such as CRP, IL-6, d-dimer and ferritin as well as acute COVID-19 severity predicted the risk for persistence of structural lung abnormalities at follow-up, whereas dyslipidemia and dysglycemia did not (Fig. 6). The gene discussed is IL6; the disease is COVID-19.